AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up — Nov 1st, 2024

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.7 billion in the third quarter of 2024, driven by a surge in demand for the phar...

Galderma Bets on Skin Drug to Turn Around Pharma Business — Nov 29th, 2024

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...